443 related articles for article (PubMed ID: 32533109)
1. Passive antibody therapy in COVID-19.
Abraham J
Nat Rev Immunol; 2020 Jul; 20(7):401-403. PubMed ID: 32533109
[TBL] [Abstract][Full Text] [Related]
2. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.
Morabito CJ; Gangadharan B
Clin Transl Sci; 2020 Sep; 13(5):835-837. PubMed ID: 32420691
[No Abstract] [Full Text] [Related]
3. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.
Halstead SB; Akkina R
Front Immunol; 2020; 11():1196. PubMed ID: 32574267
[No Abstract] [Full Text] [Related]
4. Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
Lu Y; Wang Y; Zhang Z; Huang J; Yao M; Huang G; Ge Y; Zhang P; Huang H; Wang Y; Li H; Wang W
J Immunol Res; 2020; 2020():9465398. PubMed ID: 33134398
[TBL] [Abstract][Full Text] [Related]
5. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
Rogers TF; Zhao F; Huang D; Beutler N; Burns A; He WT; Limbo O; Smith C; Song G; Woehl J; Yang L; Abbott RK; Callaghan S; Garcia E; Hurtado J; Parren M; Peng L; Ramirez S; Ricketts J; Ricciardi MJ; Rawlings SA; Wu NC; Yuan M; Smith DM; Nemazee D; Teijaro JR; Voss JE; Wilson IA; Andrabi R; Briney B; Landais E; Sok D; Jardine JG; Burton DR
Science; 2020 Aug; 369(6506):956-963. PubMed ID: 32540903
[TBL] [Abstract][Full Text] [Related]
6. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
Garraud O
Transfus Apher Sci; 2020 Aug; 59(4):102858. PubMed ID: 32631501
[No Abstract] [Full Text] [Related]
7. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.
Klasse PJ; Moore JP
Elife; 2020 Jun; 9():. PubMed ID: 32573433
[TBL] [Abstract][Full Text] [Related]
8. Audio Interview: Capitalizing on Immune Responses to Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
[No Abstract] [Full Text] [Related]
9. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
Hansen J; Baum A; Pascal KE; Russo V; Giordano S; Wloga E; Fulton BO; Yan Y; Koon K; Patel K; Chung KM; Hermann A; Ullman E; Cruz J; Rafique A; Huang T; Fairhurst J; Libertiny C; Malbec M; Lee WY; Welsh R; Farr G; Pennington S; Deshpande D; Cheng J; Watty A; Bouffard P; Babb R; Levenkova N; Chen C; Zhang B; Romero Hernandez A; Saotome K; Zhou Y; Franklin M; Sivapalasingam S; Lye DC; Weston S; Logue J; Haupt R; Frieman M; Chen G; Olson W; Murphy AJ; Stahl N; Yancopoulos GD; Kyratsous CA
Science; 2020 Aug; 369(6506):1010-1014. PubMed ID: 32540901
[TBL] [Abstract][Full Text] [Related]
10. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
Lee WS; Wheatley AK; Kent SJ; DeKosky BJ
Nat Microbiol; 2020 Oct; 5(10):1185-1191. PubMed ID: 32908214
[TBL] [Abstract][Full Text] [Related]
11. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326
[TBL] [Abstract][Full Text] [Related]
12. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
13. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
Somasundaram R; Choraria A; Antonysamy M
Int Immunopharmacol; 2020 Aug; 85():106654. PubMed ID: 32512271
[TBL] [Abstract][Full Text] [Related]
14. Antibody-based therapies for COVID-19: Can Europe move faster?
Kazatchkine MD; Goldman M; Vincent JL
PLoS Med; 2020 May; 17(5):e1003127. PubMed ID: 32369479
[TBL] [Abstract][Full Text] [Related]
15. Convalescent Plasma: Promise for COVID-19 Pandemic.
Sheikh S; Baig MA
J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
[No Abstract] [Full Text] [Related]
16. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
Brouwer PJM; Caniels TG; van der Straten K; Snitselaar JL; Aldon Y; Bangaru S; Torres JL; Okba NMA; Claireaux M; Kerster G; Bentlage AEH; van Haaren MM; Guerra D; Burger JA; Schermer EE; Verheul KD; van der Velde N; van der Kooi A; van Schooten J; van Breemen MJ; Bijl TPL; Sliepen K; Aartse A; Derking R; Bontjer I; Kootstra NA; Wiersinga WJ; Vidarsson G; Haagmans BL; Ward AB; de Bree GJ; Sanders RW; van Gils MJ
Science; 2020 Aug; 369(6504):643-650. PubMed ID: 32540902
[TBL] [Abstract][Full Text] [Related]
17. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
18. The convalescent sera option for containing COVID-19.
Casadevall A; Pirofski LA
J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489
[No Abstract] [Full Text] [Related]
19. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.
Case JB; Rothlauf PW; Chen RE; Liu Z; Zhao H; Kim AS; Bloyet LM; Zeng Q; Tahan S; Droit L; Ilagan MXG; Tartell MA; Amarasinghe G; Henderson JP; Miersch S; Ustav M; Sidhu S; Virgin HW; Wang D; Ding S; Corti D; Theel ES; Fremont DH; Diamond MS; Whelan SPJ
Cell Host Microbe; 2020 Sep; 28(3):475-485.e5. PubMed ID: 32735849
[TBL] [Abstract][Full Text] [Related]
20. Convalescent serum lines up as first-choice treatment for coronavirus.
Sheridan C
Nat Biotechnol; 2020 Jun; 38(6):655-658. PubMed ID: 32358594
[No Abstract] [Full Text] [Related]
[Next] [New Search]